Key Points
- CEO Roger Susi sold 5,000 shares on Nov. 24 at an average price of $90.36 for proceeds of $451,800, trimming his stake by 0.22% to 2,307,500 shares (worth about $208.5M).
- iRadimed beat recent quarterly estimates with $0.47 EPS (vs. $0.43 expected) and $21.2M revenue, and set Q4 2025 guidance of $0.470–0.510 EPS and FY2025 guidance of $1.840–1.880 EPS.
- The company declared a quarterly dividend of $0.17 ($0.68 annualized, ~0.8% yield), institutional investors own ~92.34% of shares, and analysts have a consensus "Moderate Buy" rating with a $87.33 target.
iRadimed Corporation (NASDAQ:IRMD - Get Free Report) CEO Roger Susi sold 5,000 shares of the stock in a transaction dated Monday, November 24th. The stock was sold at an average price of $90.36, for a total value of $451,800.00. Following the sale, the chief executive officer owned 2,307,500 shares of the company's stock, valued at $208,505,700. This represents a 0.22% decrease in their position. The transaction was disclosed in a filing with the SEC, which can be accessed through this hyperlink.
iRadimed Price Performance
IRMD stock opened at $90.31 on Tuesday. iRadimed Corporation has a 1-year low of $47.48 and a 1-year high of $91.06. The business has a 50 day simple moving average of $77.57 and a two-hundred day simple moving average of $67.63. The company has a market capitalization of $1.15 billion, a price-to-earnings ratio of 55.75 and a beta of 1.04.
iRadimed (NASDAQ:IRMD - Get Free Report) last released its quarterly earnings data on Monday, November 3rd. The medical equipment provider reported $0.47 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.43 by $0.04. iRadimed had a net margin of 26.61% and a return on equity of 23.30%. The firm had revenue of $21.20 million for the quarter, compared to analysts' expectations of $20.50 million. iRadimed has set its Q4 2025 guidance at 0.470-0.510 EPS. FY 2025 guidance at 1.840-1.880 EPS. Sell-side analysts anticipate that iRadimed Corporation will post 1.66 EPS for the current fiscal year.
iRadimed Announces Dividend
The business also recently disclosed a quarterly dividend, which will be paid on Tuesday, November 25th. Shareholders of record on Friday, November 14th will be issued a dividend of $0.17 per share. This represents a $0.68 annualized dividend and a dividend yield of 0.8%. The ex-dividend date of this dividend is Friday, November 14th. iRadimed's dividend payout ratio is 41.21%.
Institutional Trading of iRadimed
Several hedge funds and other institutional investors have recently bought and sold shares of IRMD. Roubaix Capital LLC bought a new stake in iRadimed in the first quarter worth $2,526,000. SG Americas Securities LLC lifted its holdings in shares of iRadimed by 408.8% in the 2nd quarter. SG Americas Securities LLC now owns 36,516 shares of the medical equipment provider's stock worth $2,183,000 after acquiring an additional 29,339 shares during the last quarter. Nuveen LLC purchased a new position in shares of iRadimed during the 1st quarter worth about $1,418,000. Johnson Investment Counsel Inc. bought a new position in iRadimed during the 2nd quarter valued at about $1,534,000. Finally, Algert Global LLC grew its holdings in iRadimed by 87.5% during the 3rd quarter. Algert Global LLC now owns 50,797 shares of the medical equipment provider's stock valued at $3,615,000 after purchasing an additional 23,710 shares during the last quarter. Hedge funds and other institutional investors own 92.34% of the company's stock.
Analyst Ratings Changes
Several equities research analysts have recently issued reports on the company. Weiss Ratings reaffirmed a "buy (b)" rating on shares of iRadimed in a report on Friday, October 31st. Zacks Research upgraded iRadimed to a "hold" rating in a report on Tuesday, November 4th. Roth Capital set a $90.00 price objective on iRadimed in a report on Friday, October 31st. Wall Street Zen downgraded iRadimed from a "strong-buy" rating to a "buy" rating in a research report on Sunday, October 26th. Finally, Lake Street Capital restated a "buy" rating and issued a $100.00 price target on shares of iRadimed in a research report on Monday, November 3rd. Four equities research analysts have rated the stock with a Buy rating and one has given a Hold rating to the company. Based on data from MarketBeat.com, the company has an average rating of "Moderate Buy" and a consensus target price of $87.33.
Check Out Our Latest Analysis on IRMD
About iRadimed
(
Get Free Report)
IRadimed Corp. engages in the development, manufacture, marketing, and distribution of Magnetic Resonance Imaging compatible medical devices. It also provides a non-magnetic Intravenous infusion pump system that is specifically designed for use during MRI procedures. The company was founded by Roger Susi in July 1992 and is headquartered in Winter Springs, FL.
Featured Articles
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
